title: Roles of cancer registries in enhancing oncology drug access in the Asia-Pacific region.
abstract: Cancer registries help to establish and maintain cancer incidence reporting systems, serve as a resource for investigation of cancer and its causes, and provide information for planning and evaluation of preventive and control programs. However, their wider role in directly enhancing oncology drug access has not been fully explored. We examined the value of cancer registries in oncology drug access in the Asia-Pacific region on three levels: (1) specific registry variable types; (2) macroscopic strategies on the national level; and (3) a regional cancer registry network. Using literature search and proceedings from an expert forum, this paper covers recent cancer registry developments in eight economies in the Asia-Pacific region - Australia, China, Hong Kong, Malaysia, Singapore, South Korea, Taiwan, and Thailand - and the ways they can contribute to oncology drug access. Specific registry variables relating to demographics, tumor characteristics, initial treatment plans, prognostic markers, risk factors, and mortality help to anticipate drug needs, identify high-priority research area and design access programs. On a national level, linking registry data with clinical, drug safety, financial, or drug utilization databases allows analyses of associations between utilization and outcomes. Concurrent efforts should also be channeled into developing and implementing data integrity and stewardship policies, and providing clear avenues to make data available. Less mature registry systems can employ modeling techniques and ad-hoc surveys while increasing coverage. Beyond local settings, a cancer registry network for the Asia-Pacific region would offer cross-learning and research opportunities that can exert leverage through the experiences and capabilities of a highly diverse region.
authors.affiliation: Department of Pharmacy, National University of Singapore, Singapore.
authors.forename: Swee-Sung
authors.initials: SS
authors.lastname: Soon
authors.forename: Hwee-Yong
authors.initials: HY
authors.lastname: Lim
authors.forename: Gilberto
authors.initials: G
authors.lastname: Lopes
authors.forename: Jeonghoon
authors.initials: J
authors.lastname: Ahn
authors.forename: Min
authors.initials: M
authors.lastname: Hu
authors.forename: Hishamshah Mohd
authors.initials: HM
authors.lastname: Ibrahim
authors.forename: Anand
authors.initials: A
authors.lastname: Jha
authors.forename: Bor-Sheng
authors.initials: BS
authors.lastname: Ko
authors.forename: Pak Wai
authors.initials: PW
authors.lastname: Lee
authors.forename: Diana
authors.initials: D
authors.lastname: Macdonell
authors.forename: Ekaphop
authors.initials: E
authors.lastname: Sirachainan
authors.forename: Hwee-Lin
authors.initials: HL
authors.lastname: Wee
mesh_terms: D022126:Access to Information; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001208:Asia; D003906:Developing Countries; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012042:Registries; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents